Premier Nutrition 90 Million Settlement for Alleged False Joint Juice Health Claims

Premier Nutrition’s Joint Juice line—sold as ready-to-drink beverages, shots and powders containing glucosamine—was the subject of two consolidated class actions that accused the company of deceptively advertising the products’ ability to “support” joint health without reliable scientific backing. To resolve those claims Premier agreed to roughly $90 million in settlements ($19.16M for a New York class and about $70.84M for a multi‑state class covering purchases in eight states), with payouts estimated between $10 and $50 per unit depending on the class and proof of purchase; claimants who bought more than six units must provide receipts, and remaining funds are slated for donation to the Rheumatology Research Foundation. The company denied wrongdoing but agreed to pay to avoid further litigation, with opt‑out/objection and claim deadlines and final approval hearings scheduled in spring 2026. The lawsuits were brought to remedy alleged false advertising and to deter unsupported health claims—an important enforcement theme in the supplement industry, where the Dietary Supplement Health and Education Act (DSHEA) allows structure/function statements but bars disease claims and where the Federal Trade Commission requires adequate scientific substantiation for health advertising. Similar class actions and regulatory actions in recent years have targeted makers of joint‑health and other supplements, pushing manufacturers to tighten marketing language and invest in stronger clinical evidence; for consumers, these settlements underscore the value of skepticism about bold health claims and the role of class litigation as a tool to enforce advertising standards and recover money for misled purchasers.